Biomedical Bonding AB appoints Evelina Mikaelson as new CEO
Biomedical Bonding announces today that Evelina Mikaelson has been appointed new CEO effective January 1st, 2023. This strategic appointment follows a comprehensive search process initiated after the founder and CEO Professor Michael Malkochs decision to step down as CEO as the company enters a more expansive commercial phase.
Biomedical Bonding AB is establishing a new paradigm in bone fracture fixation and restoration surgery based on its technological platform Bonevolent™ - bone-like medical adhesives and composite implants. Bonevolent™ products provide surgeons with unprecedented freedom to individualize patient implants during the treatment with emphasis on improved surgical outcome.
The Board is grateful for the time and efforts made by Michael Malkoch as CEO. The appointment of Evelina Mikaelson is an important step in the strategic plan to accelerate BMB’s commercial journey, with Prof Malkoch remaining highly active in the company as Chairman of the Board and Chief Scientific Officer, says Lena Söderström, Board member.
Evelina Mikaelson has an M.Sc. from Uppsala University in business, economics, and law and she has extensive experience in sales management from previous positions as Head of Business for various companies and business units within the Adlibris group. Most recently she holds an executive position within explorative digital development and innovation at The Agency for digital Government.
Ms Mikaelson will commence as CEO on January 1st, 2023, and her top three priorities will be to (i) lead the development and implementation of BMB’s strategic plan; (ii) deepen relationships with key opinion leaders and increase synergies with key stakeholders and (iii) ensure that sales will accelerate in the veterinary market during 2023.
For more information, please contact:
Michael Malkoch, Chairman of the Board
Phone: +46 (0) 8 121 56 755
E-mail: michael.malkoch@biomedicalbonding.com
Homepage: www.biomedicalbonding.com
Biomedical Bonding AB is a platform based Swedish MedTech company that develops cutting-edge medical adhesive fixators and novel surgical methodologies with focus on the ever-growing market of hard tissue restorations. The technological platform, Bonevolent™, is market disruptive and stands for a paradigm shift in personalized surgical interventions. BMB´s vision is to become the dominant global provider of unique adhesive products suited for fracture fixation and dental restoration market. BMB´s Bonevolent™ products are easy-to-use by clinicians, will increase patient safety, save costs and resources for health care and society as a whole. BMB is a privately held company headquartered in Stockholm, Sweden.
